Authorities from the German state of Hesse have taken aim at the practice of ‘GMP washing’ in its thriving medical cannabis market, an intervention that could have significant implications for the industry at large.
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
By Dr Sebastian Marincolo, Director of Strategic Content & Editorial, Weed.de Canadian cannabis company Organigram Global has agreed to acquire Berlin’s Sanity Group for up to 227 million euros, financed in large part by a roughly 65 million Canadian dollar capital injection from its largest shareholder, British American Tobacco (BAT).
Germany’s imports for 2025 surpassed 200 tonnes for the first time, exceeding the country’s already revised import quota for the second time in a year.
Germany’s medical cannabis imports continued their historic run in Q3 of 2025, seeing the country bring in just under 57 tonnes, though growth levels dipped slightly from Q2.
Germany’s telemedicine-fuelled expansion has driven the value of its medical cannabis market up by hundreds of millions of euros in just less than two years.
Australia and Germany are moving in opposite directions on medical cannabis imports, as both scramble to deal with the runaway growth of their medical cannabis markets.
The Federal Institute for Drugs and Medical Devices (BfArM) has announced that Germany’s estimated annual demand for medical cannabis in 2025 has already been reached, leading to a temporary suspension of new import licences.
Last month, one of Canada’s largest cannabis retailers, High Tide, thrust its way into the booming German medical cannabis market by acquiring a majority stake in Remexian Pharma GmbH in a deal worth over €27m.
